Search results
10 lip 2021 · A comprehensive range of investigations and molecular typing are essential to accurately predict prognosis, which can vary from spontaneous resolution to life-threatening disseminated disease. Targeted therapies with BRAF or MEK inhibitors have revolutionised salvage treatment.
16 maj 2021 · Histiocytoses are heterogeneous hematopoietic diseases characterized by the accumulation of CD68 (+) cells with various admixed inflammatory infiltrates. The identification of the pivotal role of the mitogen-activated protein kinase (MAPK) pathway has opened new avenues of research and therapeutic approaches.
In this Review, we describe insights into the cells of origin, molecular pathology, clinical features, and treatment strategies for some of the most common histiocytic disorders, including Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.
1 wrz 2021 · Histiocytoses are heterogeneous hematopoietic diseases characterized by the accumulation of CD68 (+) cells with various admixed inflammatory infiltrates. The identification of the pivotal role of the mitogen-activated protein kinase (MAPK) pathway has opened new avenues of research and therapeutic approaches.
1 mar 1987 · Several suggestions are made for the optimal design and performance of clinical studies aimed at evaluating potentially new therapies, including the proper identification and use of controls. In addition, a staging system is described, and a comprehensive scoring system is given.
25 paź 2012 · In the most severe cases, treatments, including thalidomide associated with neurological toxicity, pain and fatigue 29, azathioprine, or PUVA-therapy which have been shown to be effective in some adult patients, might also be considered in children (evidence: D, agreement: 1).
Histiocytosis is a generic name for a group of syndromes characterized by an abnormal increase in the number of certain immune cells called histiocytes. These include monocytes, macrophages, and dendritic cells.
